Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Esperion Therapeutics (ESPR) Share Price
News headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.0858743018377 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s analysis:
- Esperion Announces Inducement Grants Under NASDAQ Listing … – Nasdaq (nasdaq.com)
- Jefferies Group Weighs in on Esperion Therapeutics, Inc.’s Q3 2017 Earnings (NASDAQ:ESPR) (americanbankingnews.com)
- Investors watching summary on Esperion Therapeutics, Inc. (ESPR) – Wall Street Morning (wallstreetmorning.com)
- Esperion Therapeutics, Inc. (ESPR) Downgraded to Sell at Zacks Investment Research (americanbankingnews.com)
- Esperion Therapeutics (ESPR) Prices 3.1M Share Common Offering at $49/Sh (streetinsider.com)
Several equities research analysts recently commented on ESPR shares. Jefferies Group LLC started coverage on Esperion Therapeutics in a research report on Monday, July 10th. They set a “hold” rating and a $55.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $60.00 price target (up from $45.00) on shares of Esperion Therapeutics in a research note on Monday, June 26th. UBS AG reaffirmed a “buy” rating and set a $57.00 price target (up from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on Esperion Therapeutics in a research note on Friday, June 23rd. They set a “buy” rating and a $48.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $42.51.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 49.33 on Friday. The stock’s market capitalization is $1.11 billion. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38. The stock has a 50 day moving average price of $47.09 and a 200 day moving average price of $35.27.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same quarter last year, the company earned ($0.62) earnings per share. On average, equities research analysts expect that Esperion Therapeutics will post ($7.29) EPS for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.